AR-V7 (androgen receptor splice variant 7)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-AR-V7 |
|---|---|
| Type | Biomarker |
| Aliases | AR splice variant 7AR-V7AR-V7 (сплайс-варіант 7 рецептора андрогену)AR3ARv7 |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Biomarker Facts
| Biomarker type | gene_fusion |
|---|---|
| Mutation details | {"functional_impact": "Constitutively-active ligand-binding-domain-truncated AR isoform — loss of LBD = AR-targeting agents (enzalutamide, abiraterone, apalutamide, darolutamide) unable to bind", "gene": "AR", "gene_hugo_id": "HGNC:644", "variant_type": "splice"} |
| Measurement | MethodCirculating tumor cells (CTC) — Epic AR-V7 Nucleus Detect IHC (Scher 2018) OR PCR-based AR-V7 mRNA (Antonarakis 2014) OR ctDNA-based whole-transcriptome readout Unitscategorical (positive | negative) Sensitivity requirementCTC-IHC requires ≥5 CTC per 7.5 mL blood for an interpretable result; lower CTC counts are non-informative (not negative) |
| Related biomarkers | BIO-AR-MUTATION |
Notes
AR-V7 is a constitutively-active splice variant of the androgen receptor lacking the ligand-binding domain. Detected most commonly on circulating tumor cells (CTCs) by Epic AR-V7 Nucleus Detect IHC. Clinical relevance in mCRPC: AR-V7-positive patients have markedly inferior PFS/OS on abiraterone or enzalutamide compared to AR-V7-negative (PROPHECY, Antonarakis 2019, J Clin Oncol — HR ~3 for inferior survival). Switch to taxane chemotherapy (docetaxel, cabazitaxel) recovers responses. HOWEVER: FDA has NOT approved any therapy decision keyed on AR-V7; guidelines treat it as investigational / informational. Use in MDT brief to flag patients in whom ARSI-after-ARSI is unlikely to work and for whom a switch to taxane (or radioligand 177Lu-PSMA-617 if PSMA-positive) should be discussed. KB scope choice: AR-V7 ships as biomarker + RF (informational) only — no new IND, no algorithm step in this chunk. Tx-modifying signal ("switch ARSI → taxane") would require a new taxane-mCRPC IND branched on AR-V7, which is deferred.
Used By
Biomarker
BIO-AR-AMPLIFICATION- AR amplification (high-level androgen receptor copy-number gain)